NK510

Phase 2Small molecule

BBase Therapeutics (Shanghai) Co., Ltd.

NK510 is one of 122 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Colorectal CancerNot yet recruiting

Rare TumorNot yet recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Colorectal CancerPhase 1

Not yet recruiting

Rare TumorPhase 2

Not yet recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Adrucil

EElorac, Inc.

Phase 3

87 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 3

Trifluridine/tipiracil

AbbVie

Phase 3

3 4

Botensilimab

AAgenus Inc.

Phase 3

10 5

Zanzalintinib

Merck & Co.

Phase 3

1 6

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

4 7

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 3

2 8

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

1 9

Mfolfoxiri

DDominik Paul Modest

Phase 3

3 10

HR070803

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT07083349

Q4 2027

Phase 1Not yet recruiting

Colorectal Cancer

NCT07166263

Q3 2028

Phase 1Recruiting

NSCLC

NCT06097962

Q1 2031

Phase 1/2Not yet recruiting

Rare Tumor

NCT07307053

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Unknown status·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06117878·12 enrolled

Colorectal Cancer1 trial

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Not yet recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT07166263·15 enrolled

Gastric Cancer1 trial

Safety and Efficacy of NK510 to Treat Gastric Cancer

Unknown status·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06098898·9 enrolled

Systemic Lupus Erythematosus1 trial

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Not yet recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·N/A·NCT07083349·9 enrolled

Rare Tumor1 trial

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled

1 more indication

NSCLC1 trial

First-in-Human Phase I Study of TIGIT-Blocked NK510 Cells in Patients With PD-1 Refractory Advanced NSCLC

Recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06097962·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for NK510. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK510 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK510. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Base Therapeutics (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBase Therapeutics (Shanghai) Co., Ltd.

NK510

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q3 2028

Q1 2031

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Colorectal Cancer1 trial

Gastric Cancer1 trial

Systemic Lupus Erythematosus1 trial

Rare Tumor1 trial

NSCLC1 trial

References

Drug Info

Quick Facts

Related News